Literature DB >> 26337001

Human Papilloma Virus Infection Does Not Predict Response to Interferon Therapy in Ocular Surface Squamous Neoplasia.

Anat Galor1, Nisha Garg2, Afshan Nanji2, Madhura Joag2, Gerard Nuovo3, Sotiria Palioura2, Gaofeng Wang4, Carol L Karp5.   

Abstract

PURPOSE: To identify the frequency of human papilloma virus (HPV) in ocular surface squamous neoplasia (OSSN) and to evaluate differences in clinical features and treatment response of tumors with positive versus negative HPV results.
DESIGN: Retrospective case series. PARTICIPANTS: Twenty-seven patients with OSSN.
METHODS: Ocular surface squamous neoplasia specimens were analyzed for the presence of HPV. Clinical features and response to interferon were determined retrospectively and linked to the presence (versus absence) of HPV. MAIN OUTCOME MEASURES: Clinical characteristics of OSSN by HPV status.
RESULTS: Twenty-one of 27 tumors (78%) demonstrated positive HPV results. The HPV genotypes identified included HPV-16 in 10 tumors (48%), HPV-31 in 5 tumors, HPV-33 in 1 tumor, HPV-35 in 2 tumors, HPV-51 in 2 tumors, and a novel HPV in 3 tumors (total of 23 tumors because 1 tumor had 3 identified genotypes). Tumors found in the superior limbus were more likely to show positive HPV results (48% vs. 0%; P=0.06, Fisher exact test). Tumors with positive HPV-16 results were larger (68 vs. 34 mm2; P=0.08, Mann-Whitney U test) and were more likely to have papillomatous morphologic features (50% vs. 12%; P=0.07, Fisher exact test) compared with tumors showing negative results for HPV-16. Human papilloma virus status was not found to be associated with response to interferon therapy (P=1.0, Fisher exact test). Metrics found to be associated with a nonfavorable response to interferon were male gender and tumors located in the superior conjunctivae.
CONCLUSIONS: The presence of HPV in OSSN seems to be more common in lesions located in the nonexposed, superior limbus. Human papilloma virus presence does not seem to be required for a favorable response to interferon therapy.
Copyright © 2015 American Academy of Ophthalmology. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26337001      PMCID: PMC4624006          DOI: 10.1016/j.ophtha.2015.07.007

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  33 in total

Review 1.  Interferons, immunity and cancer immunoediting.

Authors:  Gavin P Dunn; Catherine M Koebel; Robert D Schreiber
Journal:  Nat Rev Immunol       Date:  2006-11       Impact factor: 53.106

2.  Detection of human papillomavirus infection in squamous tumours of the conjunctiva and lacrimal sac by immunohistochemistry, in situ hybridisation, and polymerase chain reaction.

Authors:  Y Nakamura; Y Mashima; K Kameyama; M Mukai; Y Oguchi
Journal:  Br J Ophthalmol       Date:  1997-04       Impact factor: 4.638

3.  Human papillomavirus type 18 in conjunctival intraepithelial neoplasia.

Authors:  S A Lauer; J S Malter; J R Meier
Journal:  Am J Ophthalmol       Date:  1990-07-15       Impact factor: 5.258

4.  High frequency of human papillomavirus 6/11, 16, and 18 infections in precancerous lesions and squamous cell carcinoma of the conjunctiva in subtropical Tanzania.

Authors:  Pierre Moubayed; Henry Mwakyoma; Dominik T Schneider
Journal:  Am J Clin Pathol       Date:  2004-12       Impact factor: 2.493

5.  Risk factors for conjunctival squamous cell neoplasia: a matched case-control study.

Authors:  W Tulvatana; P Bhattarakosol; L Sansopha; W Sipiyarak; E Kowitdamrong; T Paisuntornsug; S Karnsawai
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

6.  HPV infection and EGFR activation/alteration in HIV-infected East African patients with conjunctival carcinoma.

Authors:  Jing Jie Yu; Pingfu Fu; John J Pink; Dawn Dawson; Jay Wasman; Jackson Orem; Walter O Mwanda; Honglan Zhu; Xiaobing Liang; Yi Guo; William P Petros; Ronald T Mitsuyasu; Henry Wabinga; Scot C Remick
Journal:  PLoS One       Date:  2010-05-17       Impact factor: 3.240

7.  Topical interferon alpha 2b eye-drops for treatment of ocular surface squamous neoplasia: a dose comparison study.

Authors:  A Galor; C L Karp; S Chhabra; S Barnes; E C Alfonso
Journal:  Br J Ophthalmol       Date:  2009-06-02       Impact factor: 4.638

8.  Detection of human papillomavirus infection in trichilemmomas and verrucae using in situ hybridization.

Authors:  Sarah Stierman; Shaoxiong Chen; Gerard Nuovo; Jean Thomas
Journal:  J Cutan Pathol       Date:  2009-07-13       Impact factor: 1.587

9.  Human papillomavirus DNA in tissues and ocular surface swabs of patients with conjunctival epithelial neoplasia.

Authors:  J M McDonnell; P J McDonnell; Y Y Sun
Journal:  Invest Ophthalmol Vis Sci       Date:  1992-01       Impact factor: 4.799

10.  HPV type 16 in conjunctival and junctional papilloma, dysplasia, and squamous cell carcinoma.

Authors:  M Saegusa; Y Takano; M Hashimura; I Okayasu; J Shiga
Journal:  J Clin Pathol       Date:  1995-12       Impact factor: 3.411

View more
  12 in total

Review 1.  Human Papilloma Virus Vaccination and Incidence of Ocular Surface Squamous Neoplasia.

Authors:  Joy N Carroll; Zachary I Willis; Annabelle de St Maurice; Sahar Kohanim
Journal:  Int Ophthalmol Clin       Date:  2017

2.  Human papillomavirus (HPV)-associated trilateral squamous neoplasia in immunocompetent individual.

Authors:  Alfonso Iovieno; Simonetta Piana; Laura Chiesi; Cristina Fodero; Luigi Fontana
Journal:  Int Ophthalmol       Date:  2017-06-06       Impact factor: 2.031

3.  Detection of Human Papillomavirus in Squamous Lesions of the Conjunctiva Using RNA and DNA In-Situ Hybridization.

Authors:  Cornelia Peterson; Rupin N Parikh; Meleha T Ahmad; Ashley A Campbell; Yassine Daoud; Nicholas Mahoney; Sepideh Siadati; Charles G Eberhart
Journal:  Int J Mol Sci       Date:  2022-06-29       Impact factor: 6.208

4.  Diagnosis and Medical Management of Ocular Surface Squamous Neoplasia.

Authors:  Ibrahim O Sayed-Ahmed; Sotiria Palioura; Anat Galor; Carol L Karp
Journal:  Expert Rev Ophthalmol       Date:  2016-12-05

Review 5.  Ocular surface squamous neoplasia: management and outcomes.

Authors:  Roland Hӧllhumer; Susan Williams; Pamela Michelow
Journal:  Eye (Lond)       Date:  2021-02-09       Impact factor: 4.456

6.  Recombinant interferon alpha 2b for ocular surface squamous neoplasia: An efficient and cost-effective treatment modality in Asian Indian patients.

Authors:  Swathi Kaliki; Swati Singh; Sadiya Iram; Dharani Tripuraneni
Journal:  Indian J Ophthalmol       Date:  2016-10       Impact factor: 1.848

7.  Papilloma and sebaceous gland hyperplasia of the lacrimal caruncle: a case report.

Authors:  Maria Miura-Karasawa; Hiroshi Toshida; Toshihiko Ohta; Akira Murakami
Journal:  Int Med Case Rep J       Date:  2018-04-27

8.  Epidemiology of ocular surface squamous neoplasia in veterans: a retrospective case-control study.

Authors:  Logan M Smith; Shiv Lamba; Carol L Karp; Anat Galor
Journal:  Eye Vis (Lond)       Date:  2019-05-14

Review 9.  Clinical Management of Ocular Surface Squamous Neoplasia: A Review of the Current Evidence.

Authors:  Maria Vittoria Cicinelli; Alessandro Marchese; Francesco Bandello; Giulio Modorati
Journal:  Ophthalmol Ther       Date:  2018-07-20

10.  Cost-effective treatment of ocular surface squamous neoplasia for an undocumented and uninsured New York City patient: a case report.

Authors:  Norman A Saffra; Trisha S Emborgo; Codrin E Iacob; David S Kirsch
Journal:  J Med Case Rep       Date:  2020-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.